Eloralintide Research Overview

What Is Eloralintide?

Eloralintide (LY3841136, also written LY-3841136) is a synthetic, long-acting amylin analog studied for its receptor-selectivity profile within the amylin and calcitonin receptor family. Published research has focused particularly on its preferential activation of the human amylin 1 receptor (AMY1R), receptor-mediated cyclic AMP (cAMP) signaling, ligand binding, molecular design, and comparative pharmacology.

Eloralintide contains a 37-amino-acid main chain. Its structural design includes a methylene thioacetal bridge between residues 2 and 7 and a C20 fatty-diacid moiety attached at Lys26 through a linker. The lipid modification enables albumin binding and contributes to its prolonged pharmacokinetic profile.

AminoForge offers Eloralintide (LY3841136) for laboratory research use only.

Eloralintide Research Identity

Amylin Receptor Biology

Functional amylin receptors are formed when the calcitonin receptor (CTR), a class B G-protein-coupled receptor, associates with receptor activity-modifying proteins known as RAMPs. Association with RAMP1, RAMP2, or RAMP3 produces the commonly described AMY1R, AMY2R, and AMY3R receptor subtypes, respectively.

This receptor architecture is central to Eloralintide research because different amylin analogs can display different affinity and potency profiles across AMY1R, AMY3R, and CTR. Eloralintide was designed and studied specifically for a receptor profile favoring human AMY1R.

Eloralintide and AMY1R Selectivity

Published in-vitro studies characterized Eloralintide in cell lines expressing human AMY1R, human AMY3R, or human CTR. Receptor activation was measured using cAMP accumulation assays, while ligand-binding experiments were used to compare receptor affinity.

In human receptor cAMP assays, Eloralintide was approximately 12-fold more potent at AMY1R than at CTR and approximately 11-fold more potent at AMY1R than at AMY3R. Eloralintide achieved full agonism across all three human receptor systems examined.

Ligand-binding assays produced a similar pattern. Eloralintide bound human AMY1R with approximately eight-fold higher affinity than human CTR and approximately eight-fold higher affinity than human AMY3R. These findings support the description of Eloralintide as an AMY1R-selective amylin receptor agonist in human receptor systems.

Species differences are important when interpreting preclinical data. In rat receptor assays, Eloralintide retained strong selectivity over CTR but showed greater relative activity at AMY3R than it did in the corresponding human receptor assays.

Molecular Design and Albumin Binding

Eloralintide is a fatty-acid-acylated amylin analog. Its 37-amino-acid main chain contains non-coded amino-acid residues, and the native amylin disulfide bridge is replaced with a methylene thioacetal bridge. A side chain containing a saturated 20-carbon diacid is attached at Lys26 through a linker.

The C20 fatty-diacid modification supports reversible albumin binding, a peptide-engineering strategy used to extend circulating exposure. Published in-vitro experiments examined Eloralintide in the presence of human serum albumin and found that albumin binding reduced the apparent potency of lipidated peptides while Eloralintide retained its amylin-receptor selectivity over human CTR.

These structural features make Eloralintide useful for research examining how molecular stabilization, lipidation, albumin binding, and receptor selectivity interact within long-acting peptide pharmacology.

Preclinical Eloralintide Research

Published preclinical Eloralintide research has included receptor-expression systems, ligand-binding assays, rodent models, and non-human primate models.

Experimental endpoints reported in the literature include:

• AMY1R, AMY3R, and calcitonin receptor activation
• receptor-mediated cAMP signaling
• ligand-binding affinity
• species-dependent receptor pharmacology
• albumin-binding effects on receptor activity
• pharmacokinetic behavior
• food-intake and body-composition measurements in animal models
• conditioned taste-avoidance assays used for comparative amylin-agonist research

These are experimental research endpoints used to investigate amylin-receptor biology and peptide pharmacology. Findings from cell-culture, receptor-expression, animal, or other experimental models do not establish a use, benefit, or outcome in humans or animals.

Eloralintide, LY3841136, and LY-3841136

The names Eloralintide, LY3841136, and LY-3841136 refer to the same research compound in the scientific and pharmaceutical-development literature.

The LY identifier appears frequently in publications, clinical-trial records, and database entries, while Eloralintide is the recognized compound name. Using both forms when searching scientific databases can help identify relevant receptor-pharmacology, preclinical, and clinical-development literature.

Clinical Development Distinction

Eloralintide is also being investigated by Eli Lilly and Company as an investigational pharmaceutical candidate. Published Phase 1 and Phase 2 clinical studies have evaluated Lilly’s investigational Eloralintide program, and multiple Phase 3 studies are now recruiting.

Current Phase 3 programs include ENLIGHTEN-1 (NCT07321886) and ENLIGHTEN-2 (NCT07282600), among additional Eloralintide studies listed by Lilly and ClinicalTrials.gov. Eloralintide remains investigational and is not FDA approved.

AminoForge Eloralintide is not the investigational pharmaceutical product used in Eli Lilly clinical trials. AminoForge supplies Eloralintide solely as a laboratory research material. Clinical-development findings do not change the research-only status or intended use of AminoForge material.

Eloralintide in Amylin Receptor Research

Eloralintide occupies a distinct position within contemporary amylin-receptor research because its published human receptor profile favors AMY1R over AMY3R and CTR. This allows researchers to compare a more selective amylin-receptor activation profile with other compounds studied through broader or mechanistically different receptor systems.

Researchers examining related signaling frameworks may also encounter mechanistically distinct compounds within the AminoForge catalog.

• Amylin Analog is a mechanistically related but pharmacologically distinct compound studied within amylin-receptor research.
• Dual Regulator is studied through a distinct dual-receptor signaling framework.
• Triple Regulator is studied through a distinct multi-receptor signaling framework.

These compounds are not pharmacologically interchangeable. Their molecular structures, receptor targets, and experimental research frameworks differ.

Published Eloralintide Research

The following publications and databases provide useful starting points for Eloralintide and LY3841136 research:

• Briere et al.: Eloralintide discovery, molecular design, receptor pharmacology, preclinical research, and Phase 1 proof of concept
• Bhattachar et al.: Phase 1 multiple-ascending-dose Eloralintide research
• Billings et al.: 48-week randomized Phase 2 Eloralintide study
• PubChem: Eloralintide chemical identity and database record
• FDA GSRS: Eloralintide substance identity and synonyms
• ClinicalTrials.gov: ENLIGHTEN-1 Phase 3 Eloralintide study
• ClinicalTrials.gov: ENLIGHTEN-2 Phase 3 Eloralintide study
• Eli Lilly: Current Eloralintide research and development status

Eloralintide Research Material from AminoForge

View Eloralintide (LY3841136) research material for laboratory research use only. AminoForge provides batch-specific analytical documentation for research compounds through its COA and Purity resources.

For Research Use Only. Not for use in diagnostic, medical, cosmetic, or human or animal in-vivo procedures. AminoForge Eloralintide is supplied exclusively as a laboratory research material. It is not the investigational pharmaceutical product used in Eli Lilly clinical trials and is not offered as an FDA-approved drug product. Not intended to diagnose, manage, mitigate, or prevent any illness or medical condition. Not for human or animal consumption.